Clinical Circulating Tumor DNA Testing for Precision Oncology

다국어 초록 (Multilingual Abstract)

Circulating tumor DNA (ctDNA) is the portion of the cell-free DNA in the blood of cancer patients released from tumor cells via apoptosis, necrosis, or active release. From 10 mL of blood, the 4-5 mL of plasma obtained from a cancer patient contains 5-10 ng/mL of ctDNA. The plasma contains not only ctDNA of tumor origin, but also DNA from normal cells or clonal hematopoiesis. Another characteristic of ctDNA is its rapid clearance from circulation; it has a half-life of 16 minutes to 2.5 hours. Obtaining reliable results from ctDNA requires the application and approval of standardized clinical validation guidelines; however, the status of numerous ctDNA tests currently varies. The clinical use of ctDNA testing should be carefully considered based on the test’s specific needs and characteristics. Here we provide the different characteristics of ctDNA tests and information regarding their validation and approval status.

참고문헌 (Reference)

1 Duffy MJ, "Use of circulating tumour DNA(ctDNA)for measurement of therapy predictive biomarkers in patients with cancer" 12 : 99-, 2022

2 Narayan A, "Ultrasensitive measurement of hotspotmutations in tumor DNA in blood using error-suppressedmultiplexed deep sequencing" 72 : 3492-3498, 2012

3 Mosko MJ, "Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry" 18 : 23-31, 2016

4 Baer C, "Ultra-deep sequencing leads to earlier andmore sensitive detection of the tyrosine kinase inhibitor resi-stance mutation T315I in chronic myeloid leukemia" 101 : 830-838, 2016

5 Dressman D, "Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations" 100 : 8817-8822, 2003

6 Bronkhorst AJ, "Towards systematic nomenclature for cell-free DNA" 140 : 565-578, 2021

7 Menikoff J, "The common rule, upda-ted" 376 : 613-615, 2017

8 Wang X, "The DEAD-box RNA helicase 51 controls non-small cell lung cancer proliferation by regulating cell cycle progression via multiple pathways" 6 : 26108-, 2016

9 Castellanos-Rizaldos E, "Temperature-tolerant COLD-PCR reducestemperature stringency and enables robust mutation enrichment" 58 : 1130-1138, 2012

10 Detsky AS, "Sources of bias for authors of clinical practiceguidelines" 175 : 1033-, 2006

11 Sorenson GD, "Soluble normal and mutated DNA sequences fromsingle-copy genes in human blood" 3 : 67-71, 1994

12 Boyiadzis MM, "Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease" 6 : 35-, 2018

13 Colella S, "Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites" 35 : 146-150, 2003

14 Santis G, "Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR" 6 : e25191-, 2011

15 Dresser R, "Research ethics. Aligning regulations and ethics in human research" 337 : 527-528, 2012

16 Soda N, "Recent advances in liquid biopsy technologies for cancer biomarker detection" 1 : 343-375, 2022

17 Pantel K, "Real-time liquid biopsy in cancer patients : fact or fiction?" 73 : 6384-6388, 2013

18 Sacher AG, "Prospective validation of rapid plasmagenotyping for the detection of EGFR and KRAS mutations in advanced lung cancer" 2 : 1014-1022, 2016

19 Umetani N, "Prediction of breast tumor progression by integrity of free circulating DNA in serum" 24 : 4270-4276, 2006

20 Kautto EA, "Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS" 8 : 7452-7463, 2017

21 Mandel P, "Nuclear acids in human blood plasma" 142 : 241-243, 1948

22 Chen M, "Next-generation sequencing in liquid bio-psy : cancer screening and early detection" 13 : 34-, 2019

23 Ettinger DS, "NCCN guidelines insights : non-small cell lung cancer, version 2. 2021" 19 : 254-266, 2021

24 Parikh AR, "Minimal residual disease detectionusing a plasma-only circulating tumor DNA assay in patients with colorectal cancer" 27 : 5586-5594, 2021

25 Arzimanoglou II, "Microsatellite instability in human solid tumors" 82 : 1808-1820, 1998

26 Salipante SJ, "Microsatellite instability detection by next generation sequencing" 60 : 1192-1199, 2014

27 Nawroz H, "Microsatellite alterations in serum DNA of head and neck cancerpatients" 2 : 1035-1037, 1996

28 Wojdacz TK, "Methylation-sensitive high-resolution melting" 3 : 1903-1908, 2008

29 Niu B, "MSIsensor : microsatellite instability detection using paired tumor-normal sequence data" 30 : 1015-1016, 2014

30 Openshaw MR, "Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma" 123 : 1271-1279, 2020

31 Corcoran RB, "Liquid biopsy versus tumor biopsy for clinical-trial recruitment" 26 : 1815-1816, 2020

32 Ghosh RK, "Liquid biopsy : a new avenue inpathology" 30 : 138-143, 2019

33 Kohn L, "Liquid biopsies in lung cancer-time to implement research technologies inroutine care?" 5 : 278-, 2017

34 Wan JC, "Liquid biopsies come of age : towardsimplementation of circulating tumour DNA" 17 : 223-238, 2017

35 Diaz LA Jr, "Liquid biopsies : genotyping circulating tumor DNA" 32 : 579-586, 2014

36 Sturgeon CM, "Laboratory medicine practiceguidelines. Use of tumor markers in clinical practice: qualityrequirements"

37 Newman AM, "Integrated digital error suppression forimproved detection of circulating tumor DNA" 34 : 547-555, 2016

38 Lehmann-Werman R, "Identification of tissue-specific cell death using methylation patterns of circulatingDNA" 113 : E1826-34, 2016

39 Gray ES, "Genomic analysis of circulating tumor DNA using amelanoma-specific UltraSEEK Oncogene Panel" 21 : 418-426, 2019

40 Cristiano S, "Genome-wide cell-free DNA fragmentation in patientswith cancer" 570 : 385-389, 2019

41 Ofman JJ, "GRAIL and the quest for earlier multi-cancer detection" Springer Nature

42 Underhill HR, "Fragment length of circulating tumor DNA" 12 : e1006162-, 2016

43 Li D, "FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology" 4 : 32-, 2021

44 Deveson IW, "Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology" 39 : 1115-1128, 2021

45 Daniunaite K, "Epigenomic technologies for deciphering circulating tumor DNA" 55 : 23-29, 2019

46 Suva ML, "Epigenetic reprogramming in cancer" 339 : 1567-1570, 2013

47 Xia Y, "Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma : a single-arm, open label, phase II clinical trial" 10 : e004656-, 2022

48 Barra GB, "EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples" 48 : 976-981, 2015

49 U.S. Food and Drug Administration, "Drug Approvals and database" U.S. Food and Drug Administration

50 Chae YK, "Detection of minimal residual diseaseusing ctDNA in lung cancer : current evidence and futuredirections" 14 : 16-24, 2019

51 Cai Z, "Detection of microsatellite instability from circulating tumor DNA by targeted deep sequencing" 22 : 860-870, 2020

52 Bettegowda C, "Detection of circulating tumor DNA in early-and late-stage human malignancies" 6 : 224ra24-, 2014

53 Wong IH, "Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients" 59 : 71-73, 1999

54 Diehl F, "Detection and quantification of mutations in the plasma of patients with colorectal tumors" 102 : 16368-16373, 2005

55 Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease" 11 : 2968-2986, 2021

56 Zhang Y, "Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples" 23 : 141-, 2022

57 Jahr S, "DNA fragments in the blood plasma of cancer pati-ents : quantitations and evidence for their origin from apoptotic and necrotic cells" 61 : 1659-1665, 2001

58 Gong B, "Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions" 22 : 109-, 2021

59 BioRender, "Create professional science figures in minutes" BioRender

60 Chen A, "Comparison of paired cerebrospinal fluid and serum cell-free mitochondrial and nuclear DNA with copy number and fragmentlength" 34 : e23238-, 2020

61 Toro PV, "Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA" 48 : 993-998, 2015

62 Genovese G, "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence" 371 : 2477-2487, 2014

63 Keller L, "Clinical relevanceof blood-based ctDNA analysis : mutation detection andbeyond" 124 : 345-358, 2021

64 Pantel K, "Circulating tumour cells in cancer patients : challenges and perspectives" 16 : 398-406, 2010

65 Pellini B, "Circulating tumor DNA minimalresidual disease detection of non-small-cell lung cancer treated with curative intent" 40 : 567-575, 2022

66 Luo H, "Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer" 12 : eaax7533-, 2020

67 Arisi MF, "Circulating tumor DNA inprecision oncology and its applications in colorectal cancer" 23 : 4441-, 2022

68 Martinez-Saez O, "Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6inhibition and endocrine therapy" 7 : 8-, 2021

69 Merker JD, "Circulating tumor DNA analysis in patients with cancer : American Society of Clinical Oncology and College of American Pathologists Joint Review" 142 : 1242-1253, 2018

70 Dang DK, "Circulating tumor DNA : current challenges for clinical utility" 132 : e154941-, 2022

71 Diehl F, "Circulating mutant DNA to assess tumor dynamics" 14 : 985-990, 2008

72 Sorber L, "Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision ofpersonalized therapy for lung cancer patients" 107 : 100-107, 2017

73 El Messaoudi S, "Circulating cell free DNA : preanalytical considerations" 424 : 222-230, 2013

74 Schwarzenbach H, "Cell-free nucleic acidsas biomarkers in cancer patients" 11 : 426-437, 2011

75 Li L, "Cell-free circulating mitochondrial DNA content and risk of hepatocellular carcinoma in patients with chronic HBV infection" 6 : 23992-, 2016

76 Cisneros-Villanueva M, "Cell-free DNA analysis in current cancer clinical trials : a review" 126 : 391-400, 2022

77 Marrugo-Ramirez J, "Blood-based cancerbiomarkers in liquid biopsy : a promising non-invasive alternative to tissue biopsy" 19 : 2877-, 2018

78 Diehl F, "BEAMing : single-molecule PCR on microparticles in water-in-oil emulsions" 3 : 551-559, 2006

79 Engel T, "Autonomic dysfunction correlates with clinical and inflammatory activity in patients with Crohn’s disease" 21 : 2320-2326, 2015

80 Koch A, "Analysis of DNA methylation in cancer : location revisited" 15 : 459-466, 2018

81 Tost J, "Analysis and quantification of multiple methylation variable positions in CpG islands by pyrosequencing" 35 : 152-156, 2003

82 Xie M, "Age-related mutations associated with clonal hematopoietic expansion and malignancies" 20 : 1472-1478, 2014

83 Jaiswal S, "Age-related clonal hematopoiesis associatedwith adverse outcomes" 371 : 2488-2498, 2014

84 Willey JC, "Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA" 1 : 100106-, 2021

85 Stroun M, "About the possible origin and mechanism of circulating DNA apoptosis and active DNA release" 313 : 139-142, 2001

86 Norton SE, "A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR" 46 : 1561-1565, 2013

87 Cortes-Ciriano I, "A mole-cular portrait of microsatellite instability across multiple cancers" 8 : 15180-, 2017